TRISTEL plc
("Tristel" or the
"Company")
Confirmation of Interim
Results
Analyst & Investor briefing
schedule
Tristel plc (AIM: TSTL), the manufacturer of
infection prevention products, confirms it will hold the following
briefings with respect to its interim results for the six-month
period ended 31 December 2024 on Monday 24 February
2025.
Analyst
briefing
A briefing open to analysts will take place in
London on Monday 24 February 2025 at 10am. To register
and for more details please contact Walbrook PR
on tristel@walbrookpr.com
Investor
presentation
Matt Sassone, CEO, and Liz Dixon, CFO, will present
the Company's results in two separate events open to all investors.
The same presentation will be given at both events which are being
held at different times to offer convenient options for those
wishing to attend.
Two presentations will take place on Monday 24
February 2025 at the following times, the first will be held
online via the Investor Meet Company platform and the second will
be held in-person in the City of London, full details below:
1. Investor Meet Company
online presentation
Tristel management will provide a live online
presentation relating to the interim results via Investor
Meet Company at 11.30am. The presentation is open to all existing
and potential shareholders. Questions can be submitted pre-event
via your Investor Meet Company dashboard up until 9am the day
before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for
free and add to meet Tristel plc via:
https://www.investormeetcompany.com/tristel-plc/register-investor
2. In-person investor
presentation
Tristel management will provide an
in-person presentation relating to the Company's interim
results at 4.30pm, which is open to all existing and potential
shareholders. The Company welcomes investors to 85 Gresham Street,
London, EC2V 7NQ from 4.15pm for a 4.30pm start and will be
followed by refreshments.
If you would like to attend, please contact Walbrook
PR on 020 7933 8780 or email tristel@walbrookpr.com.
The results presentation will be made available on
the Company's website on the day of
results www.investors.tristel.com
For further
information please contact:
|
Tristel plc
|
Via
Walbrook PR
|
|
Matt Sassone, Chief Executive
Officer
|
www.investors.tristel.com
|
|
Liz Dixon, Chief Financial
Officer
|
|
|
|
|
|
Walbrook PR Ltd
|
Tel: 020
7933 8780 or tristel@walbrookpr.com
|
|
Paul McManus / Lianne Applegarth /
Alice Woodings
|
Mob: 07980
541 893/ 07584 391 303/ 07407 804
654
|
|
|
|
|
Cavendish Capital Markets Ltd
|
Tel: 020
7220 0500
|
|
Geoff Nash / Camilla Hume / Trisyia
Jamaludin (Corporate Finance)
|
|
|
Sunila de Silva (ECM) / Louise
Talbot (Sales)
|
|
|
|
|
| |
About Tristel
plc
Tristel plc is a global infection
prevention company focussed on the manufacture and supply of
products using its unique proprietary chlorine dioxide
(ClO2) chemistry. The Company is a market leader
in manual decontamination of medical devices, supplying
hospitals under the Tristel brand, and under the
Cache brand provides
products for sporicidal surface disinfection, a more sustainable
alternative to commonly used pre-wetted plastic wipes.
Tristel's head office and manufacturing
facility is located in Snailwell, near Cambridge, and operates
globally employing approximately 270 people across 16 subsidiaries
selling into 40+ countries. The Company targets annual revenue
growth of between 10% and 15% and an EBITDA margin of at least 25%
and the business is profitable, with no debt and has a progressive
dividend policy.
The Company has been listed on the London Stock
Exchange's AIM market since 2005 (AIM: TSTL).
For more information about Tristel's product
range please visit: https://tristel.com